Sun Pharma arm Taro recalls 17,100 kits of dandruff care kits in US
The therapeutic 2-step Kamedis Bio-Herbal Dandruff Care System is used for treating itching and flaking associated with dandruff and seborrheic dermatitis

New Delhi: Drug major Sun Pharma arm Taro Pharmaceuticals USA Inc is recalling 17,100 kits of Kamedis Bio-Herbal Dandruff Care System in the US on account of being sub-potent drug.[caption id="attachment_2159087" align="alignleft" width="380"]
Reuters[/caption]"Taro Pharmaceuticals USA Inc is recalling the drug because of it being subpotent drug: out of specification assay values on stability for the active ingredient, zinc pyrithione," the latest Enforcement Report of health regulator USFDA has said.The therapeutic 2-step Kamedis Bio-Herbal Dandruff Care System is used for treating itching and flaking associated with dandruff and seborrheic dermatitis.The voluntary nationwide ongoing recall is a class III recall, US Food and Drug Administration (USFDA) said.According to USFDA, a class III recall is initiated in "a situation in which use of or exposure to a violative product is not likely to cause adverse health onsequences".

US jobless claims fall to 187,000, signalling resilient labour market ahead of Fed meeting
NDTA asks Connaught Place shops, offices and restaurants to close by 6:30 pm today
EU slaps Google with $1 billion antitrust fine over Play Store and Search practices
Brent crude flirts with $100, reigniting inflation and forex concerns for India
Can a record May offset a shrunk international schedule and help IndiGo turn a profit?

